These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22978629)

  • 21. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the lifetime costs of rheumatoid arthritis.
    Gabriel SE; Crowson CS; Luthra HS; Wagner JL; O'Fallon WM
    J Rheumatol; 1999 Jun; 26(6):1269-74. PubMed ID: 10381041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Health-economic burden of Parkinson's disease in Portugal: a cohort study].
    Reese JP; Winter Y; Rosa MM; Rodrigues E Silva AM; von Campenhausen S; Freire R; Mateus C; Balzer-Geldsetzer M; Botzel K; Oertel WH; Dodel R; Sampaio C
    Rev Neurol; 2011 Mar; 52(5):264-74. PubMed ID: 21341221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The health burdens of Parkinson's disease.
    Chrischilles EA; Rubenstein LM; Voelker MD; Wallace RB; Rodnitzky RL
    Mov Disord; 1998 May; 13(3):406-13. PubMed ID: 9613729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset.
    Findley LJ; Wood E; Lowin J; Roeder C; Bergman A; Schifflers M
    J Med Econ; 2011; 14(1):130-9. PubMed ID: 21235405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
    Osiri M; Maetzel A; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
    Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The societal cost of schizophrenia in Sweden.
    Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
    J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The societal costs of intracerebral hemorrhage in Spain.
    Navarrete-Navarro P; Hart WM; Lopez-Bastida J; Christensen MC
    Eur J Neurol; 2007 May; 14(5):556-62. PubMed ID: 17437616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinson's disease and nursing home placement: the economic impact of the need for care.
    Vossius C; Nilsen OB; Larsen JP
    Eur J Neurol; 2009 Feb; 16(2):194-200. PubMed ID: 19146640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct medical costs associated with Parkinson's disease: a population-based study.
    Leibson CL; Long KH; Maraganore DM; Bower JH; Ransom JE; O'Brien PC; Rocca WA
    Mov Disord; 2006 Nov; 21(11):1864-71. PubMed ID: 16977632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.